Vancomycin (VCM) has been reported to elicit adverse cutaneous drug reactions. However, VCM-associated purpuric drug eruption has not been reported yet, except leukocytoclastic vasculitis. A 16-year-old Japanese girl was admitted with a respiratory infection. We initiated intravenous administration of VCM. After the start of treatment, impalpable purpuric eruption appeared on her trunk. The eruption gradually extended to her neck, legs, and arms. Skin biopsy showed vasculitis with lymphocyte infiltration in the superficial dermis. A drug lymphocyte stimulation test yielded positive results for VCM. Her cutaneous symptoms rapidly reversed after the withdrawal of VCM. To the best of our knowledge, this is the first reported case of VCM-associated purpuric drug eruption, which differs from leukocytoclastic vasculitis. We recommend that VCM-associated purpuric drug eruption should be considered in the differential diagnosis during the administration of VCM, and a drug lymphocyte stimulation test may be useful for assessment of pathogenesis.
Introduction
Vancomycin (VCM), a glycopeptide antibiotic, is widely used to treat methicillin-resistant Staphylococcus aureus infections. VCM has been reported to elicit adverse reactions, including red man syndrome, skin rash, and Stevens-Johnson syndrome (SJS).
1,2 However, there are no reports regarding VCM-associated purpuric drug eruption, except leukocytoclastic vasculitis (LV). We describe the case of a patient with VCM-associated purpuric drug eruption, which differs from LV.
Case Report
A 16-year-old Japanese girl was admitted with a respiratory infection. She had underlying Kartagener syndrome, hypoplastic left heart syndrome (post-Fontan procedure), and bronchial asthma, which were well controlled. We initiated intravenous administration of VCM and meropenem (MEPM). On day 6 after the start of treatment, an impalpable purpuric eruption appeared on her trunk ( Figure 1A) . Day 7 laboratory results were as follows: white blood cells, 27.0 × 10 9 /L (neutrophil 85.5%, lymphocyte 7.0%, and eosinophil 0.0%); hemoglobin, 9.6 g/dL; platelet count, 210 × 10 
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Discussion
Pathological findings showed not only purpura but also some features of erythema multiforme. However, her eruption did not blanch under pressure, and we therefore considered it as purpura. Sometimes, maculopapular drug eruptions exhibit purpuric spots over time. 6 However, this patient showed purpura from the beginning; thus, we diagnosed her as having purpuric drug eruptions, not maculopapular drug eruptions. Adverse reactions of the skin due to VCM are frequently observed. An et al. reported that skin rashes are the main VCM-induced adverse events. 7 In addition, some cases of VCM-associated LV, 8 including Henoch-Schönlein purpura, 9 both of which are characterized by palpable purpura on the legs with neutrophil infiltration, have been reported. Cases of LV show vasculitis with neutrophil infiltration. 10 However, the vasculitis in our case mainly comprised the infiltration of lymphocytes, not neutrophils ( Figure 2C, 2D, 2E) . Reports have described patients with purpuric drug eruption induced by epidermal growth factor receptor inhibitors such as erlotinib, 11 lenalidomide, 12 and linezolid. 13 Neither blood extravasation nor LV was observed in the pathological findings. Conversely, cases of purpura associated with another epidermal growth factor receptor inhibitor, gefitinib-associated LV, have been reported. 14 However, no previous reports have described purpuric drug eruption without LV that is associated with VCM.
We discontinued the VCM and MEPM due to concerns of VCM-induced SJS, based on the previous report.
2 Her cutaneous symptoms rapidly reversed after the withdrawal of VCM and MEPM, and no other systemic symptoms or eosinophilia were observed while her purpura disappeared. In addition, the results of a DLST suggested that her eruptions may have been a side effect of VCM. However, we could not perform a drug challenge test because of her general condition. Therefore, the pathogenic role of MEPM cannot be excluded. As the purpura appeared several days after the start of VCM administration, we believe the eruption might have been induced by a delayedtype hypersensitivity reaction.
To the best of our knowledge, this is the first reported case of VCM-associated purpuric drug eruption, which differs from LV. We recommend that VCM-associated purpuric drug eruption should be considered in the differential diagnosis during the administration of VCM, and a DLST may be useful for assessment of pathogenesis.
